

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

PPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/606,965	06/27/2003	Gan Lin Hwang	Q76295	4841
23373 7	12/08/2006		. EXAM	INER
SUGHRUE MION, PLLC			HENDRICKSON, STUART L	
2100 PENNSYLVANIA AVENUE, N.W. SUITE 800			ART UNIT	PAPER NUMBER
WASHINGTON, DC 20037			. 1754	
			DATE MAIL ED: 12/08/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

1	/
L	/

	Application No.	Applicant(s)			
0.65	10/606,965	HWANG, GAN LIN			
Office Action Summary	Examiner	Art Unit			
	Stuart Hendrickson	1754			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
 1) Responsive to communication(s) filed on 27 Second 2a) This action is FINAL. 2b) This 3) Since this application is in condition for allowant closed in accordance with the practice under Expression 	action is non-final. ce except for formal matters, pro				
Disposition of Claims					
4) ☐ Claim(s) 1,2,5-11,14-16,19-21 and 24 is/are per 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1, 2, 5-11, 14-16, 19-21, 24 is/are rejection of the company of	n from consideration.				
Application Papers	÷				
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the confidence of Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Examiner	pted or b) objected to by the E lrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) (a) Notice of References Cited (PTO-892) (b) Notice of Draftsperson's Patent Drawing Review (PTO-948) (c) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary (Paper No(s)/Mail Dat 5) Notice of Informal Pa 6) Other:	te			

Application/Control Number: 10/606,965

Art Unit: 1754

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The RCE filed is accepted.

Claims 1, 2, 5-11, 14-16, 19-21 and 24 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. There is no support for the amendment made to pg. 2 of the specification. The fact that the examiner made a guess as to the serial number was not an invitation to so amend.

Claims 1, 2, 5-11, 14-16, 19-21 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lieber 6,159,742 taken with Uchida et al. 5560898.

As to the independent claims, Lieber '742 discloses a carbon nanotube (see column 1, lines 39-41) having an organic functionalization (see column 1, lines 48-67). The formula disclosed is:

X--(L--M)_n, wherein L--M is deemed to meet the limitation of an organic functional group. Despite applicant's limitation of a nanocapsule, no difference is seen between the nanocapsule of the present invention and the nanotube of Lieber. Finally, the nanotubes are hollow (see column 2, line 24). Lieber does not discuss the purity, however Uchida teaches purifying nanotubes. It would have been obvious to one of ordinary skill in the art at the time of the invention to purify the nanotubes of Lieber because doing so provides for a high-sensitivity device without interfering species.

As to claims 2 and 5, Lieber '742 discloses a multi-walled carbon nanotube (see column 2, lines 33-39) with a diameter of 1-200 nm (see column 2, lines 24-26). In the carbon nanotube formula, n is 1 to 100 (see column 1, line 55).

Lieber teaches claim 6 because of the various possible combinations (see column 4, lines 25-40). In so far as the formula for Lieber does not match up to the present formula, it

Application/Control Number: 10/606,965

Art Unit: 1754

would have been obvious to provide bigger linking groups to be able to sorb more complicated molecules having many binding sites.

As to claims 7-9, these are process limitations and do not limit a product. No difference is seen. See, e.g., In re Brown, 459 F.2d 531,173 U.S.P.Q. 685 (CCPA 1972); In re Fessman, 489 F.2d 742, 180 U.S.P.Q. 324 (CCPA 1974).

As to claim 10, 11, and 14, Lieber teaches the functional groups of hydroxy (see column 4, lines 8-9), carboxylic acid (see column 4, lines 27-29), aldehydes and ketones (see column 4, lines 34-36). As explained above, Lieber '742 discloses a multi-walled carbon nanotube (see column 2, lines 33-39) with a diameter of 1-200 nm (see column 2, lines 24-26). In the carbon nanotube formula, n is 1 to 100 (see column 1, line 55).

As to claim 15, 16, and 19, Lieber teaches the functional groups of amides (see column 4, lines 31-34, see also column 4, lines 1-3). Lieber '742 discloses a multi-walled carbon nanotube (see column 2, lines 33-39) with a diameter of 1-200 nm (see column 2, lines 24-26). In the carbon nanotube formula, n is 1 to 100 (see column 1, line 55).

As to claim 20, 21, and 24, Lieber teaches the functional group of hydroxy (see column 4, line 8-9). Lieber '742 discloses a multi-walled carbon nanotube (see column 2, lines 33-39) with a diameter of 1-200 nm (see column 2, lines 24-26). In the carbon nanotube formula, n is 1 to 100 (see column 1, line 55).

Claims 1, 2, 5-10, 15, 19, 20 and 24 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Hiura et al. 5698175.

The discussion above concerning the similarity of the carbon is incorporated herein. Hiura teaches purifying and functionalizing hollow nanotubes. The functional groups are recited. See col. 2-3, the figures and the examples. Even though the purity is not reported per se, no patentable difference is seen since Hiura performs essentially the same process on essentially the same material and seeks to purify. Hollow multiwall nanotubes are depicted; no differences are seen in the diameter or structure.

Application/Control Number: 10/606,965 Page 4

Art Unit: 1754

Applicant's arguments filed 9/27/06 have been fully considered but they are not persuasive.

No differences have been demonstrated between the nanotubes of the references versus that of the present claims. The purity has been addressed by the addition of the Uchida reference. The term 'capsule' does not imply any particular length, diameter or aspect ratio. Lieber teaches the claimed diameter. The argument on pg. 13 as to the mechanism has not been proven in side-by-side comparison, nor do the claims limit where the functionalization occurs. The submitted references are of interest, but not applied to avoid duplication of rejection.

Any inquiry concerning this communication should be directed to examiner Hendrickson at telephone number (571) 272-1351.

Stuart Hendrickson examiner Art Unit 1754